



HHS Public Access

Author manuscript

Obesity (Silver Spring). Author manuscript; available in PMC 2019 April 01.

Published in final edited form as:

Obesity (Silver Spring). 2018 April ; 26(4): 635–640. doi:10.1002/oby.22139.

Non-nutritive Sweeteners in Weight Management and Chronic Disease: a review

Allison C. Sylvetsky^{1,2,3} and Kristina I. Rother³

¹Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Avenue NW, Washington, DC 20052

²Sumner M. Redstone Global Center for Prevention and Wellness, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Avenue NW, Washington, DC 20052

³Section on Pediatric Diabetes and Metabolism, NIDDK, NIH, 9000 Rockville Pike, Building 10, Room 8C432A, Bethesda, MD 20892

Abstract

Objectives—To critically review findings from recent studies evaluating effects of non-nutritive sweeteners (NNS) on metabolism, weight, and obesity-related chronic diseases. Biologic mechanisms that may explain NNS effects will also be addressed.

Methods—We conducted a comprehensive review of the relevant scientific literature.

Results—Most cross-sectional and prospective cohort studies report positive associations between NNS consumption, body weight, and health conditions including type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. While findings in cellular and rodent models suggest harmful effects of NNS on metabolic health, most human randomized controlled trials in humans demonstrate marginal benefits of NNS use on body weight, with little data available on other metabolic outcomes.

Conclusion—NNS consumption is associated with higher body weight and metabolic disease in observational studies. In contrast, randomized controlled trials demonstrate that NNS may support weight loss, particularly when used alongside behavioral weight loss support. Additional long-term, well-controlled intervention studies in humans are needed to determine NNS effects on weight, adiposity and chronic disease under free-living conditions.

Keywords

low-calorie sweetener; diet beverages; artificial sweeteners; metabolism; sugar; obesity; diabetes

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Contact Info: Please address all correspondence to: Allison C. Sylvetsky, PhD, The George Washington University 950 New, Hampshire Avenue NW, Washington DC 20052, asylvets@gwu.edu, Phone: 202-994-5602.

Disclosure: The authors have no conflicts of interest to disclose.

Introduction

Obesity is an urgent public health challenge in the US and worldwide¹. As obesity and its comorbidities have become unprecedentedly common, emphasis has been placed on lowering calorie intake and specifically, on reducing added sugars. Given well-established associations between added sugars, obesity², type 2 diabetes³, cardiovascular disease⁴, non-alcoholic fatty liver disease⁵, and cancer⁶, the 2015 Dietary Guidelines for Americans recommend limiting added sugar to less than 10% of total energy intake⁷ and similar guidance has been put forth by the World Health Organization⁸. As such, considerable pressure has been placed on the food industry to reformulate their products to lower sugar content and provide reduced calorie alternatives. One strategy is to substitute non-nutritive sweeteners (NNS) for added sugars, as NNS are highly sweet and palatable, but contain no or few calories.

Until recently, NNS were found primarily in beverages (e.g. diet sodas) and in sweetener packets (e.g. Equal™, Sweet N Low™, Splenda™), but are now widespread in the food supply including in condiments, reduced-calorie desserts and yogurts, cereals, snack foods, medications and hygiene products^{9,10}. We recently demonstrated that consumption of NNS has increased by approximately 200% among children and adolescents since 1999–2000¹¹, yet whether NNS are helpful or harmful for weight management and chronic disease remains a topic of controversy^{12,13}. The purpose of this review is to summarize evidence from the recent literature investigating NNS consumption in relation to appetite, metabolism, weight, and health, and to discuss physiologic mechanisms which may explain these findings.

Recommendations

Despite widespread and increasing consumption of NNS, dietary recommendations for their consumption are inconsistent across different health organizations and are often inconclusive¹⁴. For example, the 2015 Dietary Guidelines Advisory Committee scientific report¹⁵ stated, ‘added sugars should be reduced in the diet and not replaced with low-calorie [non-nutritive] sweeteners, but rather with healthy options, such as water in place of sugar-sweetened beverages.’ A joint position statement from the American Diabetes Association and American Heart Association also urged caution in the use of NNS, in stating that ‘at this time, there are insufficient data to determine conclusively whether the use of NNS to displace caloric sweeteners in beverages and foods reduces added sugars or carbohydrate intake, or benefits appetite, energy balance, body weight, or cardio-metabolic risk factors¹⁶.’ Much of this uncertainty results from a growing body of observational literature linking NNS (mainly in the form of diet soda) to a variety of health concerns¹⁷.

Observational Studies

Associations linking NNS with unfavorable health outcomes (e.g. obesity, diabetes, non-alcoholic fatty liver disease) are reported in prospective cohort studies^{17–19}, and in some cases, remain statistically significant after adjustment for BMI and other relevant covariates^{20,21}. Although observational studies are limited by their inability to establish

causality, the dose-response relationships reported, along with the fact that several plausible mechanisms may explain these findings, support a role of NNS beyond simply reverse causality.

In 2008, Fowler et al. reported a dose-response relationship between baseline consumption of NNS-containing diet beverages and weight gain 7–8 years later²². Compared to non-consumers, participants who reported drinking diet beverages were more likely to gain weight over time, even after adjustment for baseline body mass index (BMI). Interestingly, total daily energy intakes were lower among diet beverage consumers despite increased weight gain. This phenomenon has been observed in several other studies^{21,23}, suggesting that NNS may influence body weight via mechanisms independent of increasing energy intake (see Proposed Mechanisms section below). The same group reported that NNS use in form of diet beverages was associated with greater visceral adiposity after 9–10 years of follow-up, independent of baseline BMI and with minimal changes in body weight²⁴.

Results of epidemiologic studies evaluating whether NNS use is associated with a healthier or less healthy overall dietary pattern are mixed^{25–27}. Inconsistent findings are likely due to differences in the way that NNS consumers are classified and with whom they are compared. For example, Leahy et al.²⁷ recently reported that NNS consumers have improved diets compared to water consumers; yet, water consumers also included individuals consuming sugar-sweetened and NNS-sweetened beverages, as the groups were not mutually exclusive.

Positive associations between NNS use, type 2 diabetes^{28,29}, metabolic syndrome^{30,31}, cardiovascular disease³², and non-alcoholic fatty liver disease³³ have also been observed in longitudinal analyses among adults. O'Connor et al. reported a 22% higher incidence of diabetes among NNS consumers²⁸. Although attenuated after adjustment for adiposity, substitution models also indicated that replacement of sugar-sweetened beverages with diet beverages did not lower diabetes incidence²⁸. In a similar study, Ma et al.³³ demonstrated that diet beverage consumption was predictive of NAFLD, but this association was no longer statistically significant after adjustment for BMI. It is important to point out that if NNS directly contribute to weight gain and increased adiposity, adjustment for BMI in these analyses may not be appropriate³⁴. Most recently, Pase and colleagues reporting similar findings linking NNS use with stroke and dementia incidence²¹. Positive associations between NNS and other unfavorable health outcomes in longitudinal analyses have been further detailed in recent systematic reviews^{17,35}.

While well-established in adults, limited data on the associations between NNS, weight, and chronic disease are available in children³⁶. However, an emerging body of observational literature suggests that maternal ingestion of diet beverages during pregnancy may increase obesity risk in their children³⁷. Associations between maternal NNS consumption and infant weight were recently reported by two independent groups^{38,39}, and remained statistically significant after adjustment for confounders including maternal body weight, calorie intake, diet quality, and physical activity, and socio-demographic characteristics. A third group conducted a similar analysis but did not observe differences in child weight at seven years of age based on maternal NNS consumption⁴⁰. Although the biologic mechanisms connecting infant overweight to *in utero* NNS exposure have yet to be elucidated, these studies raise

questions as to whether ingestion of NNS during pregnancy may contribute to childhood obesity.

Proposed Mechanisms Linking NNS To Weight and Health Outcomes

Reverse causality and residual confounding may in part explain associations between NNS use, weight, and metabolic disease⁴¹. For example, individuals who are already overweight or at risk for diabetes or related diseases may use NNS to manage their weight or delay disease onset. Even after adjustment for relevant covariates, findings may be biased by residual confounding.

Several biological mechanisms tested *in vitro* and *in vivo* may explain these associations^{42,43}. While the potential mechanisms discussed below are not exhaustive, it is important to recognize that some mechanisms may be generalizable across NNS (e.g. sweet taste receptors), whereas others may be compound specific (e.g. only relevant for sucralose and not for aspartame)⁴³. Furthermore, these mechanisms may not be mutually exclusive.

Sweet Taste Receptors

Sweet tasting compounds, including caloric sugars (e.g. sucrose, fructose), NNS (e.g. sucralose, aspartame), and sweet proteins (e.g. thaumatin), activate the heterodimeric sweet taste receptor, T1R2/T1R3⁴⁴. Although once believed to be present exclusively in the oral cavity⁴⁵, sweet taste receptors have recently been located throughout the body. Whereas sweet taste receptor activation on taste buds triggers the release of neurotransmitters to convey sweetness to the brain, activation of sweet taste receptors extra-orally exerts different downstream effects, only some of which are presently understood⁴⁶.

Activation of pancreatic or intestinal sweet-taste receptors leads to insulin or glucagon-like-peptide 1 (GLP-1) release, respectively, as has been shown in response to NNS in *in vitro* studies^{45,47,48}. In human studies, augmentation of insulin and/or GLP-1 has been shown by our group⁴⁹⁻⁵¹ and others⁵² when administered in combination with oral glucose, although the clinical impact of the observed hormonal responses remains to be elucidated^{51,53}. However, when NNS are administered without glucose, the majority of human studies do not report changes in hormonal responses.^{54,55}

Disturbance of Relationship between Sweetness and Calories

Evolutionarily, sweet taste was indicative of calories and nutrients (e.g. fruit), yet this is not the case for NNS. It has therefore been hypothesized that the sensation of sweetness without the delivery of calories may result in a disturbance of appetite regulation and impaired metabolic signaling¹³. This concept is supported by several rodent studies, involving intermittent access to either glucose (nutritive) or saccharin (non-nutritive)^{56,57}. In one set of experiments⁵⁷, rodents were given standard chow ad libitum and plain yogurt on three days of the week. Yogurt sweetened with either sucrose or saccharin was provided three other days of the week. Using this and similar paradigms (e.g. intermittent access to sweetened solutions instead of yogurt, ad libitum access to a high-fat/high-sugar diet instead of standard chow, longer or shorter duration of study), Swithers and colleagues have repeatedly shown that rodents have higher energy intake, gain more weight, and have relative

hyperglycemia following intermittent access to saccharin compared to glucose. Similar findings have been reported following prolonged exposure to aspartame and saccharin⁵⁸, yet no differences in weight were reported by Boakes et al.⁵⁹ after repeated saccharin exposure in an analogous design⁵⁷.

Several challenges exist in generalizing the Swithers paradigm⁵⁶ to human NNS consumption⁶⁰. Whereas rodents were exposed to sweetness intermittently and received sweetness only from NNS or glucose sweetened yogurt (or solutions)⁵⁷, humans are continually exposed to a plethora of sweet foods and beverages with varying nutrient profiles. It is therefore unclear whether the same potential disturbance in conditioning between sweet taste and calories would be expected in humans. This has not been investigated in clinical studies and warrants further investigation.

Alterations in Gut Microbiota

NNS influence the microbial composition of the oral mucosa and are viewed positively by the dental community⁶¹. *In vitro* studies⁶² demonstrate that NNS including aspartame, saccharin, and sucralose have anti-microbial activity against common periodontal pathogens. It is therefore not surprising that NNS were recently shown to alter the gut microbiota, primarily in rodent models^{63–65}.

Suez et al. demonstrated that treating mice with NNS for 11 weeks resulted in glucose intolerance⁶³, and transplantation of microbiota from saccharin exposed mice to germ-free mice induced glucose intolerance among the recipients⁶³. Although results following saccharin exposure were the most robust, the authors reported that similar findings were observed after exposure to aspartame and sucralose. Alterations in the gut microbiota and glucose intolerance among saccharin exposed mice were observed in comparison to glucose-exposed mice, as well as relative to mice administered unsweetened water. While the increased volumes of caloric liquid and subsequent reduction in solid food calories and accompanying nutrients may explain differences in microbiota between saccharin and water exposed mice, this difference would not explain differences in comparison to mice consuming glucose, as liquid volumes and solid food intakes were similar between saccharin and glucose exposed mice. Notably, despite the observed microbial alterations and relative glucose intolerance, weight gain among the NNS exposed mice was similar to that observed among the nutritive sweetener or water controls.

Another rodent study demonstrated that 8 weeks of aspartame exposure altered gut bacterial composition, leading to elevated fasting glucose and impaired insulin-stimulated glucose disposal⁶⁴. Both studies showed increases in short chain fatty acid (SCFA) concentrations, specifically propionate, in the stool⁶³ and serum⁶⁴. Propionate is a substrate for gluconeogenesis and lipogenesis⁶⁶, and thus, increases in propionate may promote greater nutrient efficiency/energy harvest⁶⁷. However, the role of propionate in human health is controversial⁶⁷ and whether fecal SCFA concentrations accurately reflect the intestinal content is unclear⁶⁸.

Experimental evidence for NNS-induced alterations in gut microbiota in humans is limited⁶³. NNS exposure for one week was associated with changes in the microbiome and

glucose metabolism in a small human sample⁶³, but the lack of a control group makes these findings less interpretable. Nevertheless, further study in this area is warranted, as such findings may have important implications given the emerging role of the gut microbiome in health and disease^{69,70}.

Changes in Taste Preferences

NNS are potently sweet at low concentrations⁷¹, and relative to caloric sugars, are hundreds or thousands of times sweeter by weight, depending on the specific compound. Aspartame, for example, is 200 times more potent than sucrose and sucralose is 600 times sweeter, yet advantame, the most recently approved NNS in the United States⁷², is approximately 20,000 times sweeter than sucrose by weight⁷³. Thus, NNS can be used in small amounts to achieve comparable sweetness to caloric sugars. Some NNS also activate bitter taste receptors (e.g. saccharin and acesulfame-potassium), and thus, multiple NNS are often present in food and beverage products in order to maximize their palatability.

Given the innate liking for sweetness⁷⁴, it has been hypothesized that exposure to sweet compounds, particularly early in life, may promote a higher preference for sweet taste. Many highly sweet foods and beverages are also high in calories (e.g. brownies, cookies), and thus, enhanced sweetness preference may promote poor dietary patterns, positive energy balance, and ultimately, obesity. However, as discussed above, cross-sectional findings linking NNS to dietary patterns have been mixed²⁵⁻²⁷.

Greater sweetness preference as a result of early life exposure is also supported by findings in rodents, but has not been well-studied in humans. When pregnant rats were exposed to aspartame, their offspring ingested larger quantities of sweet foods at 60 days of life⁷⁵. Similar results were reported in offspring following exposure to acesulfame-potassium, whether exposure occurred *in utero* or during lactation⁷⁶. Analogous results were found in children who were given sugar sweetened water in infancy⁷⁷. Epidemiologic findings linking NNS consumption to overall dietary patterns in adults are mixed^{25,26,78,79} and have not been investigated in children. Gaining a better understanding of the influence of NNS on the development of taste preferences is particularly important, as infants are exposed to NNS via human breast milk⁸⁰ and exhibit a higher sweetness preference compared to older children and adults⁸¹.

Human Intervention Studies

In contrast to the epidemiologic literature, the majority of human intervention studies suggest neutral or beneficial effects of LCS use for weight management^{35,82-86}. This is particularly the case when NNS are compared to caloric sweeteners^{87,88} or when NNS are used as part of comprehensive dietary and behavioral weight loss interventions^{82,83}. While recent meta-analyses and systematic reviews disagree as to whether NNS are truly beneficial^{17,35,87}, replacement of sugar-sweetened beverages with NNS appear to be helpful for weight management, especially among individuals who are cognitively engaged in weight loss⁸⁷.

Findings are less conclusive when NNS are compared to water or unsweetened controls⁸⁷. As discussed in detail⁸⁸, randomized controlled trials showing benefits of NNS on body weight often compare NNS with sugar-sweetened beverages and lack a plain, unsweetened, control. However, several recent trials have indeed compared NNS to water⁸²⁻⁸⁴, two of which^{82,83} have reported benefits of diet beverages. Administration of diet beverages led to both significantly greater weight loss during the intervention as well as to less subsequent weight re-gain during the maintenance period⁸³. Both studies were conducted in the context of behavioral weight loss support, which may not reflect typical NNS use in the general population. The Peters et al. trial⁸³ exclusively enrolled individuals who were already habitual consumers of NNS. Thus, those assigned to the water intervention underwent a more drastic behavior change, in having to adhere to the caloric restriction, discontinue diet beverages and start drinking water.

While these trials support utility of NNS in weight loss programs, there are additional factors to consider in interpreting study findings⁸⁸. These include participant characteristics (e.g. age, race/ethnicity, genetics) and metabolic health (e.g. obese vs. lean, diabetes vs. no diabetes, overall dietary pattern etc.), length of the intervention, specific NNS used, and the extent to which administration of NNS reflects their use in real life. Importantly, most trials provide NNS as diet beverages, yet NNS are found in numerous applications and are often ingested inadvertently^{9,10}.

Beyond assessing body weight, few intervention studies have investigated effects of prolonged NNS exposure on glucose homeostasis and other metabolic outcomes. Maersk et al.⁸⁴ compared consumption of aspartame-sweetened beverages with sugar-sweetened beverages, isocaloric milk, and water. Aspartame-sweetened beverages, milk, and water all lowered liver fat, visceral adiposity, triglycerides, fasting glucose, fasting insulin, and HOMA-IR relative to sugar-sweetened beverages, with similar reductions in the aspartame and water groups. Grotz et al.⁸⁹ and Baird et al.⁹⁰ reported no differences in glucose homeostasis after sucralose exposure compared to placebo. However, the latter study was designed for toxicological safety assessment and both trials administered encapsulated sucralose to healthy, normo-glycemic volunteers. In contrast, a recent same-subject crossover study, also in healthy volunteers, reported decreased insulin sensitivity following exposure to 200 mg encapsulated sucralose (equivalent of ~three sucralose-containing diet sodas per day) compared to placebo (unpublished; abstract SUN-580 presented at the Endocrine Society Annual Meeting 2017).

Several studies have administered high doses of encapsulated aspartame to individuals with diabetes, with no adverse effects on glycemia⁹¹⁻⁹³. Similar findings have been reported in individuals with diabetes after high-dose encapsulated sucralose⁹⁴. Colagiuri et al.⁹⁵ administered aspartame to nine subjects with well-controlled type 2 diabetes at clinically relevant concentrations. While no adverse effects were reported, aspartame did not improve glycemia compared to equi-sweet quantities (9% total energy) of sucrose.

Discussion

Epidemiologic studies report positive associations between NNS consumption, obesity, and metabolic impairments and are supported by intervention studies in rodent models. In contrast, human randomized controlled trials suggest that NNS may be a useful, or at least neutral, tool for weight management, particularly when used by individuals cognitively engaged in weight loss and who habitually consume NNS. Given the discrepancies in the available evidence, the extent to which NNS are helpful or harmful for weight management and chronic disease prevention warrants further study.

The discrepant findings of observational and interventional studies may be explained by several factors. Although randomized trials are the ‘gold standard,’ they are limited by highly controlled environments that do not reflect consumption patterns in free living individuals. They also have relatively small sample sizes and short follow-up periods compared to cohort studies. Intervention studies also involve replacement of sugar-sweetened beverages with NNS, yet it is likely that NNS are used not only as a substitute but also in addition to caloric sugars. In this case, their use would be unlikely to lower total energy intake.

Meanwhile, observational studies are unable to establish cause-and-effect, are subject to inherently flawed dietary assessments⁹⁶, and can be biased by reverse causality and residual confounding. It is also difficult to discern the context in which subjects use NNS in epidemiologic analyses (e.g. whether they are cognitively engaged in behavioral weight loss or consumption NNS in an effort to adhere to a specific dietary plan). Despite these inherent limitations, findings from well-conducted epidemiologic analyses better capture free-living consumption patterns provide important insight into biomarker and health outcomes yet to be systematically tested in randomized trials.

Priorities for further research⁹⁷ include determining whether NNS are helpful for weight loss and maintenance in a manner that closely reflects their consumption, and to determine whether NNS impact glucose homeostasis in individuals with and without diabetes. In the design and interpretation of these studies, it is critical to consider the characteristics of the individuals enrolled, including habitual NNS consumption, as well as the reasons for and patterns of NNS use, among other factors.

While it is nearly impossible to replicate ‘real-life’ consumption in randomized controlled trials, investigators can meaningfully expand upon the existing body of literature by broadening the route of NNS administration to include foods and condiments. Additional emphasis should also be placed on studying effects of beverages sweetened with NNS other than aspartame. For example, of the seven randomized controlled trials evaluating NNS use and cardiometabolic health¹⁷, only in one were NNS administered in foods or packets, whereas the other six administered NNS in capsules or beverages. In one study in which aspartame was administered via packets and foods, this was in addition to aspartame-sweetened beverages⁸⁶. Given that NNS are widespread in the food supply and are often consumed unknowingly⁹, trials testing covert incorporation of NNS into a variety of foods, beverages, and condiments would better represent use in the general population¹¹.

There is also an urgent need to understand whether early life NNS exposure, including *in utero* and via breast milk, has long-term implications for diet, metabolism, and health⁹⁸. Particularly relevant to children, the widespread presence of NNS in foods and beverages, as well as in breast milk^{80,98}, leads to inadvertent exposure and reflects addition of NNS to the diet, rather than replacement. It is also important to determine if the intense sweetness contributed by adding NNS to foods and beverages (especially to those that are not typically sweet) leads to heightened expectations for sweetness throughout the diet. Addressing these and other questions⁹⁷ using longer-term, well-controlled trials, and conducted in a manner that best reflects real-life consumption, is critical to inform conclusive recommendations regarding NNS use.

Conclusion

Consumption of NNS is associated with a variety of unfavorable metabolic and health outcomes in observational studies, yet intervention trials demonstrate that NNS may benefit weight management, specifically when used in the context of calorie restriction and intentional weight loss. Additional human studies are needed to determine NNS effects on weight, metabolism, and chronic disease in a manner that closely reflects their use in real life. It is also critical to investigate NNS effects in other populations, such as infants and young children, pregnant and lactating women, and those with metabolic disease. Addressing key research questions related to NNS effects in a variety of populations and using different sweeteners (e.g. aspartame, sucralose, saccharin) and routes of administration (e.g. food, beverage, packets), will inform the role of NNS in weight management and chronic disease, and will contribute to public health recommendations promoting or discouraging their use.

Acknowledgments

Funding: This work was funded in part by the Department of Exercise and Nutrition Sciences at the George Washington University and in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.

This work was supported in part by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases and in part by the Department of Exercise and Nutrition Sciences at the George Washington University.

References

1. World Health Organization. Global Strategy on Diet, Physical Activity, and Health. 2017. <http://www.who.int/dietphysicalactivity/childhood/en/>
2. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. *Am J Clin Nutr.* 2013; 98(4):1084–1102. [PubMed: 23966427]
3. Palmer JR, Boggs DA, Krishnan S, Hu FB, Singer M, Rosenberg L. Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. *Arch Intern Med.* 2008; 168(14): 1487–1492. [PubMed: 18663160]
4. Malik VS, Popkin BM, Bray GA, Despres JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation.* 2010; 121(11):1356–1364. [PubMed: 20308626]

5. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. *Hepatology*. 2013; 57(6): 2525–2531. [PubMed: 23390127]
6. Tasevska N, Jiao L, Cross AJ, et al. Sugars in diet and risk of cancer in the NIH-AARP Diet and Health Study. *Int J Cancer*. 2012; 130(1):159–169. [PubMed: 21328345]
7. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8. 2015.
8. World Health Organization. Sugar intake for adults and children. 2015.
9. Sylvetsky AC, Greenberg M, Zhao X, Rother KI. What Parents Think about Giving Nonnutritive Sweeteners to Their Children: A Pilot Study. *Int J Pediatr*. 2014; 2014:819872. [PubMed: 25435883]
10. Sylvetsky AC, Dietz WH. Nutrient-content claims--guidance or cause for confusion? *N Engl J Med*. 2014; 371(3):195–198. [PubMed: 25014684]
11. Sylvetsky AC, Jin Y, Clark EJ, Welsh JA, Rother KI, Talegawkar SA. Consumption of Low-Calorie Sweeteners among Children and Adults in the United States. *J Acad Nutr Diet*. 2017
12. Mattes RD. Low calorie sweeteners: Science and controversy: Conference proceedings. *Physiol Behav*. 2016; 164(Pt B):429–431. [PubMed: 26773467]
13. Swithers SE. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. *Trends Endocrinol Metab*. 2013; 24(9):431–441. [PubMed: 23850261]
14. McGuire, S. *Adv Nutr*. Vol. 7. Washington, DC: US Departments of Agriculture and Health and Human Services; 2016. Scientific Report of the 2015 Dietary Guidelines Advisory Committee; p. 202-204.
15. Dietary Guidelines Advisory Committee. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Feb.2015 2015
16. Gardner C, Wylie-Rosett J, Gidding SS, et al. Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care*. 2012; 35(8):1798–1808. [PubMed: 22778165]
17. Azad MB, Abou-Setta AM, Chauhan BF, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *CMAJ*. 2017; 189(28):E929–E939. [PubMed: 28716847]
18. Fowler SP. Low-calorie sweetener use and energy balance: Results from experimental studies in animals, and large-scale prospective studies in humans. *Physiol Behav*. 2016
19. Laverty AA, Magee L, Monteiro CA, Saxena S, Millett C. Sugar and artificially sweetened beverage consumption and adiposity changes: National longitudinal study. *Int J Behav Nutr Phys Act*. 2015; 12:137. [PubMed: 26503493]
20. O'Connor L, Imamura F, Lentjes M, Khaw K, Wareham N, Forouhi N. Prospective associations and population impact of sweet beverage intake and type 2 diabetes, and effects of substitutions with alternative beverages. *Diabetologia*. 2015; 58(7):1474–1483. [PubMed: 25944371]
21. Pase MP, Himali JJ, Beiser AS, et al. Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. *Stroke*. 2017; 48(5):1139–1146. [PubMed: 28428346]
22. Fowler SP, Williams K, Resendez RG, Hunt KJ, Hazuda HP, Stern MP. Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain. *Obesity (Silver Spring)*. 2008; 16(8):1894–1900. [PubMed: 18535548]
23. Sylvetsky AC, Jin Y, Mathieu K, DiPietro L, Rother KI, Talegawkar SA. Low-Calorie Sweeteners: Disturbing the Energy Balance Equation in Adolescents? *Obesity (Silver Spring)*. 2017
24. Fowler SP, Williams K, Hazuda HP. Diet Soda Intake Is Associated with Long-Term Increases in Waist Circumference in a Biethnic Cohort of Older Adults: The San Antonio Longitudinal Study of Aging. *J Am Geriatr Soc*. 2015; 63(4):708–715. [PubMed: 25780952]
25. An R. Beverage Consumption in Relation to Discretionary Food Intake and Diet Quality among US Adults, 2003 to 2012. *J Acad Nutr Diet*. 2016; 116(1):28–37. [PubMed: 26372338]
26. Bleich SN, Wolfson JA, Vine S, Wang YC. Diet-beverage consumption and caloric intake among US adults, overall and by body weight. *Am J Public Health*. 2014; 104(3):e72–78.

27. Leahy M, Ratliff JC, Riedt CS, Fulgoni VL. Consumption of Low-Calorie Sweetened Beverages Compared to Water Is Associated with Reduced Intake of Carbohydrates and Sugar, with No Adverse Relationships to Glycemic Responses: Results from the 2001–2012 National Health and Nutrition Examination Surveys. *Nutrients*. 2017; 9(9)
28. O'Connor L, Imamura F, Lentjes MA, Khaw KT, Wareham NJ, Forouhi NG. Prospective associations and population impact of sweet beverage intake and type 2 diabetes, and effects of substitutions with alternative beverages. *Diabetologia*. 2015
29. Imamura F, O'Connor L, Forouhi NG. Positive association between artificially sweetened beverage consumption and incidence of diabetes. Reply to Sylvetsky Meni AC, Swithers SE, Rother KI [letter]. *Diabetologia*. 2015; 58(10):2457–2458. [PubMed: 26205004]
30. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. *Circulation*. 2008; 117(6):754–761. [PubMed: 18212291]
31. Nettleton JA, Lutsey PL, Wang Y, Lima JA, Michos ED, Jacobs DR Jr. Diet soda intake and risk of incident metabolic syndrome and type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA). *Diabetes Care*. 2009; 32(4):688–694. [PubMed: 19151203]
32. Gardener H, Rundek T, Markert M, Wright CB, Elkind MS, Sacco RL. Diet soft drink consumption is associated with an increased risk of vascular events in the Northern Manhattan Study. *J Gen Intern Med*. 2012; 27(9):1120–1126. [PubMed: 22282311]
33. Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. *J Hepatol*. 2015; 63(2):462–469. [PubMed: 26055949]
34. Sylvetsky Meni AC, Swithers SE, Rother KI. Positive association between artificially sweetened beverage consumption and incidence of diabetes. *Diabetologia*. 2015; 58(10):2455–2456. [PubMed: 26186883]
35. Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. *Am J Clin Nutr*. 2014; 100(3):765–777. [PubMed: 24944060]
36. Sylvetsky A, Rother KI, Brown R. Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions. *Pediatr Clin North Am*. 2011; 58(6):1467–1480. xi. [PubMed: 22093863]
37. Reid AE, Chauhan BF, Rabbani R, et al. Early Exposure to Nonnutritive Sweeteners and Long-term Metabolic Health: A Systematic Review. *Pediatrics*. 2016; 137(3):e20153603. [PubMed: 26917671]
38. Azad MB, Sharma AK, de Souza RJ, et al. Association Between Artificially Sweetened Beverage Consumption During Pregnancy and Infant Body Mass Index. *JAMA Pediatr*. 2016; 170(7):662–670. [PubMed: 27159792]
39. Zhu Y, Olsen SF, Mendola P, et al. Maternal consumption of artificially sweetened beverages during pregnancy, and offspring growth through 7 years of age: a prospective cohort study. *Int J Epidemiol*. 2017
40. Gillman MW, Rifas-Shiman SL, Fernandez-Barres S, Kleinman K, Taveras EM, Oken E. Beverage Intake During Pregnancy and Childhood Adiposity. *Pediatrics*. 2017
41. Peters JC, Beck J. Low Calorie Sweetener (LCS) use and energy balance. *Physiol Behav*. 2016
42. Mattes RD, Popkin BM. Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. *Am J Clin Nutr*. 2009; 89(1):1–14. [PubMed: 19056571]
43. Pepino MY. Metabolic effects of non-nutritive sweeteners. *Physiol Behav*. 2015; 152:450–455. [PubMed: 26095119]
44. Margolskee RF, Dyer J, Kokrashvili Z, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na⁺-glucose cotransporter 1. *Proc Natl Acad Sci U S A*. 2007; 104(38):15075–15080. [PubMed: 17724332]
45. Jang HJ, Kokrashvili Z, Theodorakis MJ, et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. *Proc Natl Acad Sci U S A*. 2007; 104(38):15069–15074. [PubMed: 17724330]

46. Fernstrom JD, Munger SD, Sclafani A, de Araujo IE, Roberts A, Molinary S. Mechanisms for sweetness. *J Nutr.* 2012; 142(6):1134S–1141S. [PubMed: 22573784]
47. Nakagawa Y, Nagasawa M, Yamada S, et al. Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion. *PLoS One.* 2009; 4(4):e5106. [PubMed: 19352508]
48. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? *Diabetes.* 2012; 61(1): 4–13. [PubMed: 22187369]
49. Brown RJ, Walter M, Rother KI. Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. *Diabetes Care.* 2009; 32(12):2184–2186. [PubMed: 19808921]
50. Brown RJ, Walter M, Rother KI. Effects of diet soda on gut hormones in youths with diabetes. *Diabetes Care.* 2012; 35(5):959–964. [PubMed: 22410815]
51. Sylvetsky AC, Brown RJ, Blau JE, Walter M, Rother KI. Hormonal responses to non-nutritive sweeteners in water and diet soda. *Nutr Metab (Lond).* 2016; 13:71. [PubMed: 27777606]
52. Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. *Diabetes Care.* 2013; 36(9):2530–2535. [PubMed: 23633524]
53. Brown RJ, Rother KI. Non-nutritive sweeteners and their role in the gastrointestinal tract. *J Clin Endocrinol Metab.* 2012; 97(8):2597–2605. [PubMed: 22679063]
54. Ford HE, Peters V, Martin NM, et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. *Eur J Clin Nutr.* 2011; 65(4):508–513. [PubMed: 21245879]
55. Brown AW, Bohan Brown MM, Onken KL, Beitz DC. Short-term consumption of sucralose, a nonnutritive sweetener, is similar to water with regard to select markers of hunger signaling and short-term glucose homeostasis in women. *Nutr Res.* 2011; 31(12):882–888. [PubMed: 22153513]
56. Swithers SE, Davidson TL. A role for sweet taste: calorie predictive relations in energy regulation by rats. *Behav Neurosci.* 2008; 122(1):161–173. [PubMed: 18298259]
57. Swithers SE, Laboy AF, Clark K, Cooper S, Davidson TL. Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats. *Behav Brain Res.* 2012; 233(1):1–14. [PubMed: 22561130]
58. de Feijo FM, Ballard CR, Foleto KC, et al. Saccharin and aspartame, compared with sucrose, induce greater weight gain in adult Wistar rats, at similar total caloric intake levels. *Appetite.* 2013; 60(1):203–207. [PubMed: 23088901]
59. Boakes RA, Kendig MD, Martire SI, Rooney KB. Sweetening yoghurt with glucose, but not with saccharin, promotes weight gain and increased fat pad mass in rats. *Appetite.* 2016; 105:114–128. [PubMed: 27189382]
60. Glendinning JI. Do low-calorie sweeteners promote weight gain in rodents? *Physiol Behav.* 2016; 164(Pt B):509–513. [PubMed: 26836277]
61. Gupta P, Gupta N, Pawar AP, Birajdar SS, Natt AS, Singh HP. Role of sugar and sugar substitutes in dental caries: a review. *ISRN Dent.* 2013; 2013:519421. [PubMed: 24490079]
62. Prashant GM, Patil RB, Nagaraj T, Patel VB. The antimicrobial activity of the three commercially available intense sweeteners against common periodontal pathogens: an in vitro study. *J Contemp Dent Pract.* 2012; 13(6):749–752. [PubMed: 23403996]
63. Suez J, Korem T, Zeevi D, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature.* 2014; 514(7521):181–186. [PubMed: 25231862]
64. Palmnas MS, Cowan TE, Bombhof MR, et al. Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat. *PLoS One.* 2014; 9(10):e109841. [PubMed: 25313461]
65. Abou-Donia MB, El-Masry EM, Abdel-Rahman AA, McLendon RE, Schiffman SS. Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. *J Toxicol Environ Health A.* 2008; 71(21):1415–1429. [PubMed: 18800291]
66. den Besten G, Lange K, Havinga R, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. *Am J Physiol Gastrointest Liver Physiol.* 2013; 305(12):G900–910. [PubMed: 24136789]

67. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol*. 2006; 40(3):235–243. [PubMed: 16633129]
68. Daly K, Darby AC, Shirazi-Beechey SP. Low calorie sweeteners and gut microbiota. *Physiol Behav*. 2016
69. Backhed F. Programming of host metabolism by the gut microbiota. *Ann Nutr Metab*. 2011; 58(Suppl 2):44–52. [PubMed: 21846980]
70. Hansen TH, Gobel RJ, Hansen T, Pedersen O. The gut microbiome in cardio-metabolic health. *Genome Med*. 2015; 7(1):33. [PubMed: 25825594]
71. Antenucci RG, Hayes JE. Nonnutritive sweeteners are not supernormal stimuli. *Int J Obes (Lond)*. 2015; 39(2):254–259. [PubMed: 24942868]
72. United States Food and Drug Administration. Department of Health and Human Services. Food Additives Permitted for Direct Addition to Food for Human Consumption; Advantame. 2014.
73. Scalfani A, Ackroff K. Advantame sweetener preference in C57BL/6J mice and Sprague-Dawley rats. *Chem Senses*. 2015; 40(3):181–186. [PubMed: 25560795]
74. Ventura AK, Mennella JA. Innate and learned preferences for sweet taste during childhood. *Curr Opin Clin Nutr Metab Care*. 2011; 14(4):379–384. [PubMed: 21508837]
75. von Poser Toigo E, Huffell AP, Mota CS, Bertolini D, Pettenuzzo LF, Dalmaiz C. Metabolic and feeding behavior alterations provoked by prenatal exposure to aspartame. *Appetite*. 2015; 87:168–174. [PubMed: 25543075]
76. Zhang GH, Chen ML, Liu SS, et al. Effects of mother's dietary exposure to acesulfame-K in Pregnancy or lactation on the adult offspring's sweet preference. *Chem Senses*. 2011; 36(9):763–770. [PubMed: 21653241]
77. Mennella JA, Jagnow CP, Beauchamp GK. Prenatal and postnatal flavor learning by human infants. *Pediatrics*. 2001; 107(6):E88. [PubMed: 11389286]
78. Piernas C, Tate DF, Wang X, Popkin BM. Does diet-beverage intake affect dietary consumption patterns? Results from the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial. *Am J Clin Nutr*. 2013; 97(3):604–611. [PubMed: 23364015]
79. Gibson SA, Horgan GW, Francis LE, Gibson AA, Stephen AM. Low Calorie Beverage Consumption Is Associated with Energy and Nutrient Intakes and Diet Quality in British Adults. *Nutrients*. 2016; 8(1)
80. Sylvetsky AC, Gardner AL, Bauman V, et al. Nonnutritive Sweeteners in Breast Milk. *J Toxicol Environ Health A*. 2015; 78(16):1029–1032. [PubMed: 26267522]
81. Mennella JA. Ontogeny of taste preferences: basic biology and implications for health. *Am J Clin Nutr*. 2014; 99(3):704S–711S. [PubMed: 24452237]
82. Tate DF, Turner-McGrievy G, Lyons E, et al. Replacing caloric beverages with water or diet beverages for weight loss in adults: main results of the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial. *Am J Clin Nutr*. 2012; 95(3):555–563. [PubMed: 22301929]
83. Peters JC, Wyatt HR, Foster GD, et al. The effects of water and non-nutritive sweetened beverages on weight loss during a 12-week weight loss treatment program. *Obesity (Silver Spring)*. 2014; 22(6):1415–1421. [PubMed: 24862170]
84. Maersk M, Belza A, Stodkilde-Jorgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. *Am J Clin Nutr*. 2012; 95(2):283–289. [PubMed: 22205311]
85. de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. *N Engl J Med*. 2012; 367(15):1397–1406. [PubMed: 22998340]
86. Blackburn GL, Kandors BS, Lavin PT, Keller SD, Whatley J. The effect of aspartame as part of a multidisciplinary weight-control program on short- and long-term control of body weight. *Am J Clin Nutr*. 1997; 65(2):409–418. [PubMed: 9022524]
87. Rogers PJ, Hogenkamp PS, de Graaf C, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. *Int J Obes (Lond)*. 2015

88. Sylvetsky AC, Blau JE, Rother KI. Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research. *Rev Endocr Metab Disord*. 2016
89. Grotz VL, Pi-Sunyer X, Porte D Jr, Roberts A, Richard Trout J. A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis. *Regul Toxicol Pharmacol*. 2017; 88:22–33. [PubMed: 28502831]
90. Baird IM, Shephard NW, Merritt RJ, Hildick-Smith G. Repeated dose study of sucralose tolerance in human subjects. *Food Chem Toxicol*. 2000; 38(Suppl 2):S123–129. [PubMed: 10882825]
91. Nehrling JK, Kobe P, McLane MP, Olson RE, Kamath S, Horwitz DL. Aspartame use by persons with diabetes. *Diabetes Care*. 1985; 8(5):415–417. [PubMed: 3902420]
92. Okuno G, Kawakami F, Tako H, et al. Glucose tolerance, blood lipid, insulin and glucagon concentration after single or continuous administration of aspartame in diabetics. *Diabetes Res Clin Pract*. 1986; 2(1):23–27. [PubMed: 3522147]
93. Stern SB, Bleicher SJ, Flores A, Gombos G, Recitas D, Shu J. Administration of aspartame in non-insulin-dependent diabetics. *J Toxicol Environ Health*. 1976; 2(2):429–439. [PubMed: 1011296]
94. Grotz VL, Henry RR, McGill JB, et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. *J Am Diet Assoc*. 2003; 103(12):1607–1612. [PubMed: 14647086]
95. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. *Am J Clin Nutr*. 1989; 50(3):474–478. [PubMed: 2672774]
96. Subar AF, Freedman LS, Tooze JA, et al. Addressing Current Criticism Regarding the Value of Self-Report Dietary Data. *J Nutr*. 2015; 145(12):2639–2645. [PubMed: 26468491]
97. Bright OMWD, White MS, Bleich SN, Foreyt J, Franz M, Johnson G, Manning BT, Mattes R, Pi-Sunyer X, Schneeman B, Parrott JS, Sylvetsky A, Ziegler P, Chung M. Research Priorities for Studies Linking Intake of Low Calorie Sweeteners and Potentially Related Health Outcomes. *Current Developments in Nutrition*. 2017; 1(7)
98. Rother KI, Sylvetsky AC, Schiffman SS. Non-nutritive sweeteners in breast milk: perspective on potential implications of recent findings. *Arch Toxicol*. 2015; 89(11):2169–2171. [PubMed: 26462668]

What is already known?

- Non-nutritive sweeteners are widely consumed by children and adults and are found in numerous foods, beverages, and personal care products.
- Non-nutritive sweetener use is associated with higher body weight and metabolic abnormalities in epidemiologic studies.
- Replacing sugar-sweetened beverages with beverages containing non-nutritive sweeteners may be beneficial for weight loss when used as part of comprehensive lifestyle interventions.

What does this review add?

- This review highlights discrepancies between the observational and interventional literature in humans and discusses potential factors which may explain these discordant findings.
- Potential mechanisms linking non-nutritive sweeteners to obesity and chronic disease are discussed and their relevance is examined in the context of human consumption.
- Key future research needs related to non-nutritive sweeteners and their effects are highlighted.